Cellectis S.A.

Cellectis S.A. shareholders held a Combined General Meeting, approving all but one of the proposed resolutions. Key approvals included the 2025 annual and consolidated financial statements, the renewal of four Board of Directors members, and authorizations for share buybacks and various capital increases. A proposal to increase share capital for a company savings plan was rejected by shareholders.

Cellectis S.A. held its shareholders general meeting on June 25, 2026, in Paris. During the meeting, approximately 55.84% of voting rights were exercised. Shareholders adopted resolutions 1 through 29 and rejected resolution 30, aligning with the recommendations of the board of directors. Detailed results are available on the company's website.

Cellectis S.A. shareholders approved all 30 proposed resolutions at the Combined General Meeting held on December 31, 2025. Key approvals included the company's 2025 financial statements, the renewal of four Board of Directors members, and authorizations for share buybacks and capital reductions. Shareholders also granted the Board broad delegations of authority for future capital increases, including those with cancellation of preferential subscription rights for various investor categories and an "At-the-market" program. All resolutions were carried, demonstrating strong shareholder support for the company's proposals.

Cellectis held its shareholders general meeting on June 25, 2026, where approximately 55.84% of voting rights were exercised. Shareholders adopted resolutions 1 through 29 and rejected resolution 30. All voting results were consistent with the recommendations provided by the company's board of directors.

Cellectis presented positive final Phase 1 results for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and preliminary data for eti-cel in r/r B-cell non-Hodgkin lymphoma (r/r B-NHL) at the EHA 2026 Congress. Lasme-cel achieved a 100% overall response rate in the target Phase 2 population, with a manageable safety profile, and its pivotal Phase 2 trial is now recruiting. Eti-cel demonstrated an 88% ORR in its optimal dose cohort, with findings suggesting alemtuzumab optimization can enhance CAR-T expansion and response.

Cellectis presented final Phase 1 data for lasme-cel (BALLI-01) in relapsed/refractory B-cell acute lymphoblastic leukemia and preliminary data for eti-cel (NATHALI-01) in relapsed/refractory B-cell non-Hodgkin lymphoma at EHA 2026. The BALLI-01 trial achieved a 100% overall response rate and 57% complete remission in the target Phase 2 population, demonstrating a manageable safety profile. The NATHALI-01 study showed an 88% overall response rate and 63% complete response in the optimal dose cohort, with findings suggesting alemtuzumab optimization. Both pivotal Phase 2 trials are open for recruitment, with key data expected in Q4 2026.

Cellectis announced that the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy candidate. This designation is for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), recognizing the potential to address unmet medical needs. The RMAT designation is supported by promising efficacy and a manageable safety profile from Phase 1 BALLI-01 data, with final data to be presented at the 2026 EHA Congress. The pivotal Phase 2 BALLI-01 trial is currently open for enrollment.

Cellectis S.A. announced its total number of shares in capital and voting rights as of May 31, 2026. The company reported 100,691,658 shares in capital and 106,134,467 total voting rights.

Cellectis S.A. announced its Combined General Meeting of Shareholders to be held on June 25, 2026, to approve the 2025 financial statements, which reported an annual loss of 61,849,605 and a consolidated loss of $67,592,758. Shareholders will also vote on renewing four board members, authorizing a share buyback program up to 10 million, and approving multiple delegations of authority for future capital increases, including those with cancellation of preferential subscription rights for various investor categories. Additionally, the meeting will address an amendment to the Chairman's age limit and authorizations for stock options and free share allocations.

Cellectis announced it will hold its annual general meeting on June 25, 2026, at 2:30 p.m. CET. The meeting will take place at the Biopark auditorium in Paris, France. The notice of meeting has been made available on the company's investor relations website.